AdaptHealth's Q4 2022 results showed an 11.1% increase in net revenue compared to Q4 2021, driven by non-acquired growth of 5.3%. However, the company reported a net loss attributable to AdaptHealth Corp. of $2.6 million, and Adjusted EBITDA decreased by 7.7% compared to the same period last year. The company updated its financial guidance for fiscal year 2023.
Net revenue increased by 11.1% to $780.3 million compared to Q4 2021.
Non-acquired growth contributed 5.3% to the net revenue increase.
Net loss attributable to AdaptHealth Corp. was $2.6 million, or $(0.02) per diluted share.
Adjusted EBITDA decreased by 7.7% to $146.0 million compared to Q4 2021.
The Company is updating its initial financial guidance for fiscal year 2023, as follows: •Net revenue of $3.160 billion to $3.240 billion (previously $3.210 billion to $3.290 billion); •Adjusted EBITDA of $650 million to $710 million (previously $690 million to $750 million); •Total capital expenditures representing 10-12% of net revenue (previously 9-11% of net revenue).
Analyze how earnings announcements historically affect stock price performance